Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats

El-Salhy,Magdy; Umezawa,Kazuo

doi:10.3892/ijmm.2016.2560

Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats

Authors:
- Magdy El-Salhy
- Kazuo Umezawa
View Affiliations

Affiliations: Division of Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, 5416 Stord, Norway, Department of Molecular Target Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan
Published online on: April 12, 2016 https://doi.org/10.3892/ijmm.2016.2560
Pages: 1457-1464
Copyright: © El-Salhy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to elucidate the anti-inflammatory effects of the two novel anti-inflammatory substances, 3-[(dodecylthiocarbonyl)‑methyl]-glutarimide (DTCM-G) and dehydroxymethylepoxyquinomicin (DHMEQ), on DSS-induced colitis in rats. For this purpose, rats with dextran sulfate sodium (DSS)-induced colitis were randomly divided into 3 groups with 10 animals in each group as follows: i) the control group, which received 0.5 ml of 0.5% carboxymethyl cellulose (CMC; vehicle), ii) rats that received DTCM-G (20 mg/kg body weight in 0.5% CMC; the DTCM-G group), and iii) rats that received DHMEQ (15 mg/kg body weight in 0.5% CMC; the DHMEQ group). The animals were sacrificed after the 5-day treatment period, and tissue samples were taken from their colons and sectioned for histological evaluation. The tissue sections were stained with hematoxylin and eosin, and immunostained for leukocytes, lymphocytes, macrophages/monocytes and mast cells. The disease activity index (DAI), histological grading of colitis, and densities of several types of submucosal immune cells were compared between the controls, and the DTCM-G and DHMEQ groups. The DAI values were significantly lower in both the DTCM-G and DHMEQ groups than in the control group. The total scores for the histological grading of colitis were also significantly lower in the DTCM-G and DHMEQ groups than in the control group. The submucosal densities of leucocytes, lymphocytes, macrophages/monocytes and mast cells were significantly lower in the DTCM-G and DHMEQ groups than in the control group. Our findings indicate that the anti-inflammatory and anticancer effects of DTCM-G and DHMEQ, and the absence of any associated toxicity render them excellent therapeutic candidates for clinical use in the treatment of colitis.

View Figures

View References

1	Prantera C and Marconi S: Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Therap Adv Gastroenterol. 6:137–156. 2013. View Article : Google Scholar : PubMed/NCBI
2	Cosnes J, Gower-Rousseau C, Seksik P and Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 140:1785–1794. 2011. View Article : Google Scholar : PubMed/NCBI
3	Carter MJ, Lobo AJ and Travis SP: IBD Section, British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut. 53(Suppl 5): V1–V16. 2004. View Article : Google Scholar
4	Podolsky DK: Inflammatory bowel disease. N Engl J Med. 347:417–429. 2002. View Article : Google Scholar : PubMed/NCBI
5	Podolsky DK: The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 16:933–943. 2002. View Article : Google Scholar : PubMed/NCBI
6	Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 126:1504–1517. 2004. View Article : Google Scholar : PubMed/NCBI
7	Loftus EV Jr and Sandborn WJ: Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 31:1–20. 2002. View Article : Google Scholar : PubMed/NCBI
8	Betteridge JD, Armbruster SP, Maydonovitch C and Veerappan GR: Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis. 19:1421–1427. 2013. View Article : Google Scholar : PubMed/NCBI
9	Yang SK, Loftus EV Jr and Sandborn WJ: Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis. 7:260–270. 2001. View Article : Google Scholar : PubMed/NCBI
10	Goh K and Xiao SD: Inflammatory bowel disease: A survey of the epidemiology in Asia. J Dig Dis. 10:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sands BE: New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 86:1045–1064. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sands BE: The risks and benefits of early immunosuppression and biological therapy. Dig Dis. 30(Suppl 3): 100–106. 2012. View Article : Google Scholar
13	Prantera C, Pallone F, Brunetti G, Cottone M and Miglioli M; The Italian IBD Study Group: Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology. 103:363–368. 1992.PubMed/NCBI
14	Lopez A, Billioud V, Peyrin-Biroulet C and Peyrin-Biroulet L: Adherence to anti-TNF therapy in inflammatory bowel diseases: A systematic review. Inflamm Bowel Dis. 19:1528–1533. 2013. View Article : Google Scholar : PubMed/NCBI
15	Danese S: Anti TNF-alpha treatment for Crohn' disease: 'ménage a trois'. Curr Drug Targets. 11:136–137. 2010. View Article : Google Scholar : PubMed/NCBI
16	Danese S and Angelucci E: New and emerging biologics in the treatment of inflammatory bowel disease: Quo vadis? Gastroenterol Clin Biol. 33(Suppl 3): S217–S227. 2009. View Article : Google Scholar
17	Danese S, Angelucci E, Malesci A and Caprilli R: Biological agents for ulcerative colitis: Hypes and hopes. Med Res Rev. 28:201–218. 2008. View Article : Google Scholar
18	Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P and Reinisch W: Review article: The role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment Pharmacol Ther. 37:855–866. 2013. View Article : Google Scholar : PubMed/NCBI
19	Danese S, Colombel JF, Reinisch W and Rutgeerts PJ: Review article: Infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 33:857–869. 2011. View Article : Google Scholar : PubMed/NCBI
20	Danese S, Semeraro S, Armuzzi A, Papa A and Gasbarrini A: Biological therapies for inflammatory bowel disease: Research drives clinics. Mini Rev Med Chem. 6:771–784. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ota E, Takeiri M, Tachibana M, Ishikawa Y, Umezawa K and Nishiyama S: Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. Bioorg Med Chem Lett. 22:164–167. 2012. View Article : Google Scholar
22	Shibasaki S, Yamashita K, Goto R, Wakayama K, Tsunetoshi Y, Zaitsu M, Igarashi R, Haga S, Ozaki M, Umezawa K and Todo S: Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. Transplantation. 95:542–550. 2013. View Article : Google Scholar
23	Funakoshi T, Yamashita K, Ichikawa N, Fukai M, Suzuki T, Goto R, Oura T, Kobayashi N, Katsurada T, Ichihara S, et al: A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. J Crohn's Colitis. 6:215–225. 2012. View Article : Google Scholar
24	El-Salhy M, Umezawa K, Gilja OH, Hatlebakk JG, Gundersen D and Hausken T: Amelioration of severe TNBS induced colitis by novel AP-1 and NF-κB inhibitors in rats. ScientificWorldJournal. 2014:8138042014. View Article : Google Scholar
25	Elson CO, Sartor RB, Tennyson GS and Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology. 109:1344–1367. 1995. View Article : Google Scholar : PubMed/NCBI
26	Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S, Inoue J and Umezawa K: Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 10:865–869. 2000. View Article : Google Scholar : PubMed/NCBI
27	Grimstad T, Bjørndal B, Cacabelos D, Aasprong OG, Omdal R, Svardal A, Bohov P, Pamplona R, Portero-Otin M, Berge RK and Hausken T: A salmon peptide diet alleviates experimental colitis as compared with fish oil. J Nutr Sci. 2:e22013. View Article : Google Scholar : PubMed/NCBI
28	Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, Shebani K, Moore F, O'Brien M and Becker JM: NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol. 279:G1298–G1306. 2000.PubMed/NCBI
29	Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238–249. 1993.PubMed/NCBI
30	Mao JW, Huang YS, Tang HY, Bi J, Liu YF and Wang YD: Flt3/Flt3L participates in the process of regulating dendritic cells and regulatory T cells in DSS-induced colitis. Gastroenterol Res Pract. 2014:4835782014. View Article : Google Scholar : PubMed/NCBI
31	Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG and Van Rees EP: Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 114:385–391. 1998. View Article : Google Scholar : PubMed/NCBI
32	Low D, Nguyen DD and Mizoguchi E: Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther. 7:1341–1357. 2013.PubMed/NCBI
33	Takeiri M, Tachibana M, Kaneda A, Ito A, Ishikawa Y, Nishiyama S, Goto R, Yamashita K, Shibasaki S, Hirokata G, et al: Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. Inflamm Res. 60:879–888. 2011. View Article : Google Scholar : PubMed/NCBI
34	Umezawa K: Possible role of peritoneal NF-κB in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ. Biomed Pharmacother. 65:252–259. 2011. View Article : Google Scholar : PubMed/NCBI
35	Yamamoto M, Horie R, Takeiri M, Kozawa I and Umezawa K: Inactivation of NF-kappaB components by covalent binding of (−)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem. 51:5780–5788. 2008. View Article : Google Scholar : PubMed/NCBI
36	Ariga A, Namekawa J, Matsumoto N, Inoue J and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethy-lepoxyquinomicin. J Biol Chem. 277:24625–24630. 2002. View Article : Google Scholar : PubMed/NCBI
37	Schonthaler HB, Guinea-Viniegra J and Wagner EF: Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis. 70(Suppl 1): i109–i112. 2011. View Article : Google Scholar : PubMed/NCBI
38	Matsushima A, Kaisho T, Rennert PD, Nakano H, Kurosawa K, Uchida D, Takeda K, Akira S and Matsumoto M: Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J Exp Med. 193:631–636. 2001. View Article : Google Scholar : PubMed/NCBI
39	Umezawa K, Ariga A and Matsumoto N: Naturally occurring and synthetic inhibitors of NF-kappaB functions. Anticancer Drug Des. 15:239–244. 2000.
40	Brassesco MS, Roberto GM, Morales AG, Oliveira JC, Delsin LE, Pezuk JA, Valera ET, Carlotti CG Jr, Rego EM, de Oliveira HF, et al: Inhibition of NF-κB by dehydroxymethylepoxyquinomicin suppresses invasion and synergistically potentiates temozolomide and γ-radiation cytotoxicity in glioblastoma cells. Chemother Res Pract. 2013:5930202013.
41	Celegato M, Borghese C, Umezawa K, Casagrande N, Colombatti A, Carbone A and Aldinucci D: The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. Cancer Lett. 349:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
42	Fukushima T, Kawaguchi M, Yorita K, Tanaka H, Takeshima H, Umezawa K and Kataoka H: Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma. Neurooncol. 14:19–28. 2012.
43	Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, Miyajima A, Horiguchi Y, Nakashima J, Umezawa K, Shigematsu N and Oya M: Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br J Cancer. 107:652–657. 2012. View Article : Google Scholar : PubMed/NCBI
44	Lampiasi N, Azzolina A, Umezawa K, Montalto G, McCubrey JA and Cervello M: The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett. 322:35–44. 2012. View Article : Google Scholar : PubMed/NCBI
45	Lampiasi N, Umezawa K, Montalto G and Cervello M: Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells. Biochim Biophys Acta. 1843:2662–2673. 2014. View Article : Google Scholar : PubMed/NCBI
46	Miyanishi N, Suzuki Y, Simizu S, Kuwabara Y, Banno K and Umezawa K: Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochem Biophys Res Commun. 403:154–159. 2010. View Article : Google Scholar : PubMed/NCBI
47	Mino K, Ozaki M, Nakanishi K, Haga S, Sato M, Kina M, Takahashi M, Takahashi N, Kataoka A, Yanagihara K, et al: Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci. 102:1052–1058. 2011. View Article : Google Scholar : PubMed/NCBI
48	Suzuki K, Aiura K, Matsuda S, Itano O, Takeuchi O, Umezawa K and Kitagawa Y: Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer. Clin Exp Metastasis. 30:381–392. 2013. View Article : Google Scholar
49	Yasuda A, Kondo S, Nagumo T, Tsukamoto H, Mukudai Y, Umezawa K and Shintani S: Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo. Oral Oncol. 47:334–339. 2011. View Article : Google Scholar : PubMed/NCBI